Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (NCT00315380)
Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis
🩺 Plain-English Summary (8th-Grade Level)
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — San Diego, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- University of California San Diego — San Diego, California
- National Jewish Health — Denver, Colorado
- Brigham and Women's Hospital — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Cleveland Clinic Foundation — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- University of Pittsburgh — Pittsburgh, Pennsylvania
- University of Utah — Salt Lake City, Utah
- St. Joseph's Healthcare — Hamilton, Ontario
- Mount Sinai Hospital — Toronto, Ontario
- medius KLINIK KIRCHHEIM — Kirchheim unter Teck,
- AOU Meyer IRCCS — Florence,
- Cambridge University Hospitals Nhs Foundation Trust — Cambridge,
- Imperial College Healthcare NHS Trust/ Imperial College London — London,
- Guy'S and St Thomas' Nhs Foundation Trust — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Eosinophilic Granulomatosis With Polyangiitis
- Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis — Denver, Colorado
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) — Denver, Colorado
Explore by condition: All Eosinophilic Granulomatosis With Polyangiitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.